ID   CAL-39
AC   CVCL_1109
SY   CAL 39; CAL39; Centre Antoine Lacassagne-39
DR   CLO; CLO_0002184
DR   CLDB; cl630
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473368
DR   cancercelllines; CVCL_1109
DR   Cell_Model_Passport; SIDM00935
DR   ChEMBL-Cells; CHEMBL3308716
DR   ChEMBL-Targets; CHEMBL1075410
DR   Cosmic; 924107
DR   Cosmic; 1995358
DR   Cosmic-CLP; 924107
DR   DepMap; ACH-002091
DR   DSMZ; ACC-187
DR   DSMZCellDive; ACC-187
DR   EGA; EGAS00001000978
DR   GDSC; 924107
DR   GEO; GSM1669651
DR   IARC_TP53; 27146
DR   LINCS_LDP; LCL-1294
DR   PharmacoDB; CAL39_171_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1109
DR   Wikidata; Q54808399
RX   PubMed=20164919;
RX   PubMed=21573363;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 30 hours (Note=At 34th passage) (PubMed=21573363); ~50-70 hours (DSMZ=ACC-187).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Arg2597Ter (c.7789C>T); ClinVar=VCV001937208; Zygosity=Homozygous (Cosmic-CLP=924107; DepMap=ACH-002091).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Homozygous (Cosmic-CLP=924107; DepMap=ACH-002091).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.88%; Native American=0.78%; East Asian, North=0%; East Asian, South=1.64%; South Asian=9.08%; European, North=26.43%; European, South=59.19% (PubMed=30894373).
CC   Derived from site: In situ; Vulva; UBERON=UBERON_0000997.
ST   Source(s): Cosmic-CLP=924107; DSMZ=ACC-187
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,13
ST   D16S539: 9,11
ST   D18S51: 16,17
ST   D19S433: 13
ST   D21S11: 30
ST   D2S1338: 21
ST   D3S1358: 17
ST   D5S818: 12
ST   D7S820: 8
ST   D8S1179: 16
ST   FGA: 21
ST   Penta D: 12,13
ST   Penta E: 7,12
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C4052; Vulvar squamous cell carcinoma
DI   ORDO; Orphanet_494448; Vulvar squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   76Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 37
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21573363; DOI=10.3892/ijo.3.2.293;
RA   Gioanni J., Grosgeorge J., Zanghellini E., Mazeau C., Gaudray P.,
RA   Ettore F., Formento P., Demard F.;
RT   "Characterization of CAL39, a new human cell-line derived from a
RT   vulvar squamous-cell carcinoma.";
RL   Int. J. Oncol. 3:293-297(1993).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//